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Available online 29 May 2014Silymarin, a standardised extract of Silybum marianum (milk thistle), comprises mainly of
silybin, with dehydrosilybin (DHSB), quercetin, taxifolin, silychristin and a number of other
compounds which are known to possess a range of salutary effects. Indeed, there is evidence for
their role in reducing tumour growth, preventing liver toxicity, and protecting a number of
organs against ischemic damage. The hepatoprotective effects of silymarin, especially in
preventing Amanita and alcohol intoxication induced damage to the liver, are a well established
fact. Likewise, there is weighty evidence that silymarin possesses antimicrobial and anticancer
activities. Additionally, it has emerged that in animal models, silymarin can protect the heart,
brain, liver and kidneys against ischemia reperfusion injury, probably by preconditioning. The
mechanisms of preconditioning are, in general, well studied, especially in the heart. On the
other hand, the mechanism by which silymarin protects the heart from ischemia remains
largely unexplored. This review, therefore, focuses on evaluating existing studies on silymarin
induced cardioprotection in the context of the established mechanisms of preconditioning.
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Silymarin, a well knownmulticomponent extract from the
seeds of the milk thistle (Sylibum marianum), has been used
for the treatment of various ailments, mainly those of the
liver, for over two thousand years [1]. Interest in this vener-
able remedy has not been lost with the advent of the system-
atic scientific approach and modern biochemical methods,
and there are now over four hundred clinical trials using
silymarin or its components for liver related diseases alone
[2]. In this day and age, silymarin is available as an extract
from several major suppliers, each with its own standard
composition, which varies dramatically between suppliers
and appears to depend on variety and growing condition of
the crop [3–5]. Typically, silymarin contains around 50%
silybin, 20% silychristin, 10% silydianin, 5% isosilybin and be-
tween 10 and 30% of a typically unidentified organic polymer
fraction formed from the above compounds. Additionally, a
minor fraction of other flavanols including 2,3-dehydrosilybin
(DHSB), quercetin, taxifolin, kaempferol and others is present
[5,6]. Some of the constituents, including silybin, are present
as a mixture of stereoisomers with contrasting biological
activities [7,8] (Fig. 1). It is understandable therefore, that
small changes in the chemical composition of the extract can
have a strong influence on its biological activity. On the other
hand, this is largely irrelevant when working with the
purified, individual components of silymarin. It should be
noted that as a consequence of consisting of a number of
bioactive compounds, silymarin does not have a single
molecular target. Indeed, many of its components, as will
become apparent from the discussion below, target more
than one enzyme or process. Whilst this can be viewed as a
pharmacologist's nightmare, the same pharmacologist may
find that it can also become a treasure trove of interesting
medicinal compounds and precursors. The milk thistle would
serve well for this purpose, owing partially due to its wide
range and ease of cultivation.
It is understandable, therefore, that more and more at-
tention is being devoted to the possible protective effects of
silymarin on organs besides the liver. As such studies exam-
ining protection by silymarin against ischemic damage to
kidney, liver, brain and heart have emerged. This is most
likely tied to the discovery, and more recently improved un-
derstanding, of pre- and post-conditioning. Applicable to tis-
sue that has been subject to ischemia, these closely related
biological phenomena prevent a large part of the damage
that occurs upon its reperfusion.Whilst preconditioningmust
be applied during the early window, at least 24 h prior to
ischemia, or the late window around 30 min prior to ische-
mia, post-conditioning can be applied immediately upon re-
perfusion. Given the unpredictable nature of infarcts, post-
conditioning is undoubtedly more valuable as a treatment.
Preconditioning, on the other hand, could be availed of when
ischemia can be anticipated, for example during surgery or
transport of organs [9,10]. The most common, and most
clinically relevant, examples of this kind of injury are the
heart and brain, where ischemic events manifest themselves
as heart attacks and strokes respectively. Arguably, due to the
increased window for treatment, pre- and post-conditioning
of the heart makes a better example. Both pre- and post-
conditioning can be induced either by a series of brief ischemia-reperfusion cycles, in which case they are known as ischemic
pre- or post-conditioning (IPC), or by pharmacological agents,
in which case they are known as pharmacological pre- or post-
conditioning. The former was discovered in 1986 [11] using an
open chest dog model, whilst the later arguably in 1984 [12].
Whilst IPC is the better known of the two, pharmacological
preconditioning is probablymore applicable in practice, aswell
as serving as a useful tool for the study of the mechanisms
involved in IPC.
2. Preconditioning and silymarin
Following occlusion of the blood supply, ischemic tissue
will eventually die by necrosis (curiously the 1986 study had
already established a limit for the length of ischemia which
preconditioning can protect against [11]). It follows that
reperfusion became the main form of intervention for
myocardial infarction. This led to the discovery of ischemia
reperfusion (IR) injury of the heart, which occurs, as the name
suggests, when following a prolonged period of ischemia,
blood supply is restored to the ischemic tissue, paradoxically
causing a rise in cell death. This is proposed to occur because
the kick-starting of respiration, in cells where most of the ion
gradients have all but collapsed, sets up the perfect conditions
for the opening of the mitochondrial permeability transition
pore (mPTP) and the subsequent induction of apoptosis. In
accordance with this model, ischemic cells rapidly become
hypoxic and switch to glycolysis for their source of adenosine
triphosphate (ATP) hence becoming acidified. At the same time,
levels of reactive oxygen species (ROS) increase and levels of
ATP drop along with the activity of the Na+/K+ ATPase. Due to
the increased proton concentration, i.e. intracellular acidifica-
tion and reduced activity of the Na+/K+ ATPase, the Na+/H+
exchanger causes an influx of Na+. This reverses ion-flux
through the Na+/Ca2+ antiporter, increasing the intracellular
concentration of Ca2+. Under normal conditions this increase
in ROS and Ca2+ would be sufficient to open the mPTP and
induce apoptosis, however, as low pH inhibits mPTP opening,
apoptosis does not occur in ischemic cells. Instead the damage
occurs upon reperfusion, when the mitochondrial pH begins to
normalise with the restoration of the mitochondrial H+
gradient and all the conditions for the opening of the mPTP
have been met [13,14].
Pre- and post-conditioning, must therefore function either
by reducing calcium concentrations in the cells [15–17],
limiting over-production or accumulation of ROS or increasing
the mPTP threshold [13,18]. In fact it has been shown that
pharmacological opening of mPTP with atractyloside prevents
preconditioning [19–21], whilst preventing this opening with
cyclosporin A (CsA) induces preconditioning in rabbit hearts
[20]. The latter prevents the binding of Cyclophilin D [22],
whilst the former is a direct inhibitor of the adenine nucleotide
transporter (ANT) [23]. Rasola et al. [18] suggest that glycogen
synthase kinase 3β (GSK3β) and protein kinase Cε (PKCε) may
be responsible for the phosphorylation and hence modulation
of mPTP components. It appears that when phosphorylated
and hence inhibited by PKCε, GSK3β shifts from the voltage
dependent anion channels (VDAC) to ANT binding [24].
This coincides with reduced VDAC phosphorylation and
may be central to pre- and post-conditioning [25] as there is
evidence that GSK3β inhibition is a central and crucial step in
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lenge this notion in favour of the model where GSK3β is a
marker of preconditioning [19–21,29–31], the evidence for the
central role of PKCε in preconditioning is solid [27,29,32–41].
It is therefore possible that other targets of PKCε, such as
respiratory chain components or aldehyde dehydrogenase 2
(ALDH2), may be responsible for raising mPTP threshold
[42–44]. PKCε itself can be activated by an increase in ROS
[45], DAG [36], or by phosphorylation by Erk or protein kinase
G (PKG) [15,38,46–50]. In turn, pharmacological precondition-
ing can be achieved through a number of receptors which are
known to activate Erk, PKG and phospholipase C (PLC). Thus, as
summarised in Fig. 2, it has been established that stimulation
through adrenergic, ouabain, acetylcholine, opioid, bradykinin,
oestrogen and adenosine receptors triggers preconditioningFig. 1. A schematic diagram of several of the more important components of silym
silydianin.[38–40,50–63]. Taking into account the number of receptors
and downstream components involved in pre- and post-
conditioning, along with the number of their possible inter-
actions of the main components of silymarin, the scope of
any attempt to pin down the mechanism responsible for
silymarin's cardioprotective activity becomes apparent.
Silymarin, and silybin in particular, is known to protect a
number of organs, including brain, liver, kidney and the
gastrointestinal tract. Silymarin's hepatoprotective proper-
ties are especially well researched, with over two hundred
clinical trials [2].
In addition, several studies have investigated the potential
of silymarin in protecting gastric mucosa [64], liver [65],
kidney [66,67] and brain against IR injury [68,69]. Curiously,
unlike Wang et al. [68], Hou et al. [69] found that whilstarin; taxifolin, silybin, isosilybin, quercetin, dehydrosilybin, silychristin and
Fig. 2. Diagram outlining the pathways of preconditioning, as evidenced from various models of preconditioning, and the possible interaction points for the
components of silymarin that are summarised in this paper. Black arrows indicate interactions between components of the pathways, with blue curly arrows
indicating signal transduction by second messengers. Green arrows and red stubbed arrows indicate potential interaction by silymarin's components.
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protection against IR injury, silybin did not. This leads to the
fascinating possibility that components of silymarin besides
silybin, are primarily responsible for the cardioprotective ef-
fects of silymarin. As we point out in the Introduction section
(vide supra) it is unlikely that silymarin as a multicomponent
extract has a single molecular target. This is exemplified by
studies whose findings highlight quercetin's ability to protect
various tissue types against IR Injury [70–75]. To add to this, a
number of studies examined taxifolin's cardioprotective ef-
fects in diabetic cardiomyopathy [76] and its ability to pre-
condition against cerebral ischemia [77]. As quercetin and
taxifolin are relatively minor components of silymarin, the
importance of their contribution to preconditioning by silybin
remains unclear. Furthermore, unlike resveratrol, whose
cardioprotective effects are known to be mediated via the
activation of SIRT1 and inhibition of cyclo-oxygenase (COX)
[78–80], it is not quite so clear-cut as to which of silymarin's
components could be responsible for the protective effects of
the extract. If anything, the situation in the field is somewhat
similar to that of cardioprotection by garlic, where it is
thought that the effect is attained by a mix of anti-oxidant
activity, COX inhibition and potentiation of H2S signalling
[81–86], but definitive proof is lacking, probably because of
the complexity of the biochemical cocktail.
There are additional studies evidencing silymarin's action
as a cardioprotective agent. The first was a simple IR study in
rat hearts, published in 1992 that found silybin to cause a
modest reduction in infarct size [87]. This study went largely
unnoticed, probably due to language barriers, and the next
study on the cardioprotective properties of silybin was not
published until fifteen years later. In this study Rao andViswanath [88] used in vivo rat infarct models to test the
effect of week-long feeding of various doses of silymarin on IR
injury, using both biochemical markers and infarct size mea-
surements. Silymarin feeding was found to cause a dose de-
pendent decrease in infarct size, lipid peroxide level and
glutamate oxaloacetate transaminase levels whilst increasing
glutathione transferase and catalase levels [88]. Silymarinwas
also found to normalise levels of biomarkers of Adriamycin
cardiotoxicity, which are elevated by this highly toxic chemo-
therapeutic agent [89]. Since whole silymarin was used in
both studies, it is unclear which of its components was re-
sponsible for the cardioprotective effect [88,89]. As the dam-
age associated with the use of Adriamycin is thought to be
caused by free radicals, the authors of the study suggested
that the antioxidant properties of silymarin are likely re-
sponsible for its cardioprotective effect in this instance,
although reduction of mPTP sensitivity to free radicals via
the various preconditioning pathways remains an equally
valid, if untested, possibility [89]. In an investigation of pre-
conditioning by quercetin in an open chest rat model, Jin et al.
[72] found a reduction in the levels of markers of inflamma-
tion and improved functional recovery in quercetin treated
rats, but no reduction in infarct size when rats were treated
with 1 mg/kg quercetin prior to ischemia. The study did not
rule out a reduction in infarct size at higher concentrations
of quercetin. In fact, a simulated ischemia study in cardio-
myocytes later found that long term quercetin treatment
protected the cells against simulated IR injury [75]. It is
noteworthy that inhibition of PKCε was found to prevent
cardioprotection in this study, as this suggests that quercetin
mediated cardioprotection is true preconditioning, rather
than simple reduction in the ROS levels due to its antioxidant
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mTOR phosphorylation in rat models of cerebral ischemia
treated with silybin. As Akt phosphorylation should eventually
lead to PKCε phosphorylation this re-enforces the hypothesis
that the components of silymarin act via the canonical
preconditioning pathways. It is also possible that the protective
effect is due to reduction of inflammatory damage to the tissue,
as a reduction in NF-κB levels was seen in models of stroke
[68,69]. Conversely, a number of the studies mentioned above
found increased levels of antioxidant levels and decreased levels
of oxidative stress upon treatment with silymarin, silybin or
quercetin [73,90,91]. At the same time studies of quercetin
preconditioning have pointed to reduced inflammation [72],
inhibition of MMP [71] and reduced oxidative stress [74], but as
none of these studies compared quercetin to well established
methods of preconditioning, it is unclear whether these are
effects specifically caused by quercetin or are a general trait of
preconditioning. There have been no studies to date testing
preconditioning or cardioprotection by purified isosilybin,
silychristin or silydianin. However, since silychristin and
silydianin have been found to offer at least partial protection
to cardiomyocytes against anthracycline toxicity and are
generally reported to be antioxidants, it is not unlikely that
they may also offer protection against IR injury [92–95].
3. Actions of silymarin that may be related
to preconditioning
Apart from the finding that PKCε activity is required for
quercetin preconditioning, no study has examined the role of
other preconditioning pathways in cardioprotection by this
compound [75]. On the other hand, a wealth of information
about silymarin's components, has been gleaned from bio-
chemical and molecular studies. These studies have shown
several promising directions for unravelling silymarin's mech-
anisms in preconditioning.
There is a strong argument for the involvement of
silymarin in the final steps of the preconditioning pathway.
Its constituent flavonolignans and flavonols, with the excep-
tion of silydianin and silychristin under certain conditions,
have been found to act as antioxidants and radical scavengers,
which, as reduction in free radical concentrations increases
mPTP threshold, may go some way towards explaining their
protective effects [95–97]. This is not, however, the whole
story, as the concentrations at which these compounds begin
to act as antioxidants were quite high and show a dependence
on the system used to investigate them [93,95,98]. In the
study by Gabrielova et al. [93], DHSB was found to inhibit free
radical formation between 10 and 100 μM in cell based and
cell free systems, whilst effectively preventing free radical
formation at sub-micromolar concentrations in isolated
mitochondria. The authors suggest that as well as acting as a
free radical scavenger, DHSB acts as an uncoupler, hence
preventing mitochondrial free radical generation [93]. Simi-
larly, silydianin and silychristin were found to be mildly
pro-oxidative in models of copper induced LDL oxidation [95],
butwere found to act as antioxidants in a doxorubicin-iron based
models of oxidative damage [98], as well as being capable
scavengers of phenylglyoxyl ketyl radicals [99]. Curiously, silybin
also proved to be a scavenger in this model. Dorta et al. [94]
investigated the antioxidant properties of quercetin and taxifolin.Aside from making certain structural deductions, they found
quercetin to be both the stronger anti-oxidant and a respiratory
chain uncoupler [94]. It should be noted, that working on
isolatedmitochondria, similar to Gabrielova et al. [93], this group
found that DHSB has antioxidant activities at submicromolar
concentrations — indirect evidence that the substances interact
directlywith the biological system. Silydianin and silychristin, on
the other hand, may act as pro-oxidants under certain
conditions, but this is unlikely to have a significant effect on the
overall properties of silymarin in all systems [95]. The depen-
dence of the components' activity on concentration and model
system is further highlighted by additional examples. Certain
studies have found that at 20 μM and 50 μM, quercetin can
preserve cell viability following treatment with H2O2 [100,101].
Whilst another study found that at 50 μMquercetin can increase
mPTP opening [102]. The possibility that high concentrations of
quercetin increasemPTP opening is supported by ANT inhibition
by the compound [102]. There is also some evidence that DHSB
interacts with ANT and may be transported by the ion carrier,
although it is not clear whether the direct effect of this
interaction would be to raise or lower the threshold of mPTP
[93]. As such, there is evidence that the components of
silymarin may exert a concentration dependent effect on
mPTP opening, which may either assist or inhibit
preconditioning.
Upstreamof themitochondria silymarin's components has
been shown to interact with a number of cellular pathways
and the receptors. Aside from direct evidence that silybin B
(but not the A stereoisomer), taxifolin and quercetin activate
ERs [8], which, in and of itself, should be enough to cause
preconditioning [62,63,103–106], there are also hints that
these compounds may modulate other receptors. Adenosine
and Ouabain receptors, for example, both bind adenosine,
marking them as potential candidates for interaction with
DHSB and quercetin, as the former was found to bind the
nucleotide binding domain of proteins [107] and the latter
appears to be an inhibitor of ATPases and ANT [108]. There
was also a study by Angelone et al. [109] that suggests that
quercetin's inotropic and lusitropic effects are directly
dependent on adrenergic receptors. This is further supported
by a study by Zhou et al. [110], which found silybin to reverse
isoproterenol induced damage in a model of cardiac hyper-
trophy. As adrenergic stimulants such as isoproterenol, which
in the long term induce deleterious effects such as hypertro-
phy, cause ischemic preconditioning in the short term, it is
possible that an agent that prevents AR stimulant induced
hypertrophy would also antagonise the mechanisms leading to
cardiac preconditioning [110]. On the other hand, the modified
coupling to G proteins by long term isoproterenol exposure may
make the model inapplicable for preconditioning. There is also
the possibility that silybin also inhibits ARβ3, which would lead
to preconditioning. It should be noted that the study by Zhou et
al. [110] did not elucidate whether silybin directly interacts with
ARβs or whether more downstream components of the AR
signalling pathway were affected. This raises the possibility that
this pathway could be targeted by silymarin via the adenosine
binding motifs of AC or PKA. In addition, at around 10 μM,
quercetin was found to inhibit phosphodiesterase 4 (PDE4)
[111], which is one of the PDE isoforms responsible for negative
feedback in PKA/cAMP signalling. Curiously inhibition of PDE
by silymarin components is not a recent discovery [112,113].
Compound Effect Model(s) References
Silybin Cardioprotection Aortic banding
mouse model
[115]
Preconditioning Open chest Sprague–
Dawley rats,
[87]
Open chest Wistar rat
model
[88]
Long–Evans rats
ischemic stroke
[69]
BALB/C mouse
ischemic tourniquet-
gastrocnemius
[91]
Sprague Dawley rats
ischemic stroke
[68]
Antioxidant In vitro
assays (silybin
dihemisuccinate)
[96]
Copper induced
oxidation model
(silybin, silydianin,
silychristin)
[95]
PDE inhibitor In vitro assays,
partially purified
beef heart PDEs
[112]
HIF inhibitor HeLa and HEP-3 cell
model
[120]
GLUT inhibitor 3T3-L1 and CHO cell
models
[127]
ER stimulation T47D.Luc cell culture
luciferase reporter
model
[8]
Hypoxia induced
VEGF release
HeLa and HEP-3 cell
model
[120]
Anti-inflammatory Mouse tail-flick and
writhing model
[128]
Anti-proliferative
activity
UV irradiated SKH
hairless mice
[111]
Akt modulation HeLa and HEP3B
culture model
(stimulation)
[120]
HUVEC (inhibition) [116]
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could also explain the result seen by Angelone et al. [109]. This
may also shed light on the increased cAMP levels and
vasodilation observed in HUVECs (human umbilical vein
endothelial cells) and aortic rings respectively [114]. A com-
prehensive study by Ai et al. [115] on the effects of silybin in
cardiac hypertrophy found that the compound inhibited the
phenomenon by blocking EGFR phosphorylation, as well as
that of the components of the downstream Erk and Akt path-
ways. GSK3β phosphorylation was decreased when mice were
subjected to aortic banding and increased in sham operated
mice.Whilst this effectwas recapitulated by theAng II inhibitor
SU1428, the deactivation of Akt and Erk pathways is the op-
posite effect to that observed in preconditioning. Although the
experimental model used here was not one of IR injury and
therefore might not accurately reflect silybin's effects in IR
injury, the study did suggest that silybin is not the component
of silymarin responsible for preconditioning. Incidentally, this
was not the only study to show reduced Akt phosphorylation
and cell growth upon treatment with silybin. In a study even
further removed from our ideal model of IR injury, Singh et al.
[116] showed reduced proliferation of HUVEC cells and
reduced phosphorylation of Akt at Ser 473 and Thr 308 fol-
lowing 48 h treatment with 10–50 mg/ml silybin. Similarly,
Deep et al. [117,118] found that in culture models of prostate
cancer isosilybin A decreases Akt phosphorylation, whilst
isosilybin B increases it. Curiously in this case upregulation of
Akt phosphorylation resulted in a reduction in androgen
expression, whilst downregulation increased stimulated apo-
ptosis. Likewise, both topical pretreatmentwith, and feeding of
silybin to, hairless mice prior to UV (ultraviolet) carcinogenesis
slowed tumour growth, reducing levels of phosphorylated Akt,
Erk and Jnk [119]. In another in vitro tumourmodel, silybinwas
found to inhibit the activity of hypoxia induced factor 1 (HIF-1)
and the p70S6K/mTOR pathway, whilst paradoxically activat-
ing Akt [120]. Curiously, the same study found that hypoxia
induced vascular endothelial growth factor (VEGF) release was
inhibited by silybin. This echoes the investigation of Deep et al.
[121], where the growth of prostate cancer xenografts was
slowed by silybin and isosilybin with a decrease in angiogenic
markers such as VEGF. Whilst these cancer models are far
removed from our ideal models of IR injury, they nevertheless
demonstrate that the mechanism of action of silybin differs
somewhat from what one would expect of a pharmacological
preconditioning agent. Another component of silymarin,
quercetin was found to preserve cell viability following treat-
ment with H2O2, although studies reached opposite conclu-
sions as to the activation of Erk1/2 during these effects
[100,101]. This could be a result of the differences in
concentrations of quercetin applied and cell lines used;
Ishikawa and Kitamura [100] used 20 μM quercetin, whilst
Youl et al. [101] showed increased Erk phosphorylation at
50 μMand above. Additionally quercetin reduced expression of
Erb2 and 3 (EGFR family) in a HT-29 in vitro model of colon
cancer. This was accompanied by a reduction in the activation
of the IP3K/Akt pathway. It is unclear, whether findings in this
model would translate to a reduction in EGFR expression
in cardiomyocytes [122]. Furthermore, in vitro taxifolin was
found to alter gene expression from the antioxidant response
element (ARE), including the down-regulation of EGF and
fibroblast growth factor (FGF), although the exact consequencesof this for IR preconditioning are difficult to interpret [3]. Thus, it
is difficult to reconcile the models showing down-regulation of
Akt signalling with cardioprotective effects of silybin seen by
Chen et al. [87] and the neuroprotective effects seen byHou et al.
[69] andWang et al. [68] (especially as the last study specifically
observed up-regulation of Akt signalling). In fact, given the
weight of evidence showing silybin to be an antiproliferative
agent which reduces Akt activation, we can only surmise that
highly nuanced differences in pathway coupling, specific to the
different models, are responsible for the effects observed. It is
also possible that prior to ischemia, silybin does in fact down-
regulate Akt signalling in the models used by Hou et al. and
Wang et al. [68,69], with a rebound in Akt activation upon
occlusion. Another, somewhat unrelated, possibility men-
tioned above is that inhibition of the cyclooxygenase pathway
by silybin and taxifolin would reduce the damage caused by
inflammation [123,124]. In fact silybin and silydianin have
been found to reduce production of hydroxyl radicals by poly-
morphonuclear neutrophils (PMNs) [125]. A further study by
Zielinska-Przyjemska et al. [126] suggests that, at least in the
case of silydianin, this is due to increased apoptosis of PMNs
due to the induction of caspase 3. This fits in with the sugges-
tion that silymarin prevents IR injury, at least in part, by
reducing inflammation [68,69].(continued on next page)
Compound Effect Model(s) References
UV irradiated SKH
hairless mouse
(inhibition)
[119]
Wistar rat IR model
(inhibition)
[88]
Antiviral (HCV) Cell culture and
ex vivo models.
[129]
Dehydrosilybin Mitochondrial
Uncoupling
Rat myocyte,
mitochondria and
in vitro models
[85]
Antioxidant
activity
Ex vivo and
microsomal assays
[130]
Review [131]
GLUT inhibition 3T3-L1 and CHO
cell models
[120]
Topoisomerase
inhibition
EPI and FIB cell
nuclear extracts
[132]
In vitro
topoisomerase
assay
[133]
MDR inhibition T5-HeLa membrane
vesicle preparations
[108]
Review [134]
Sensitive and
resistant cancer
cell lines
[135]
MRP1-BHK1 cell
lines and membrane
vesicle models
[107]
Plasmodium
falciparum strains
[136]
Taxifolin Anti-inflammatory Rat paw oedema
model
[137]
EGF/FGF
downregulation
HCT 116 cell model [3]
ER stimulation T47D.Luc cell culture
luciferase reporter
model
[8]
Quercetin Cardioprotection Neonatal rat
myocytes, simulated
ischemia model
[75]
Open chest Sprague–
Dawley rat model
[72]
Simulated ischemia,
embryonic rat
ventricular cells
[73]
Preconditioning Ischemic kidney
Sprague Dawley
rat model
[74]
Ischemic stroke
C57BL6 mouse
model
[71]
Vasodilation HUVECs & aortic
rings
[114]
MPTP opening Rat kidney cortex
mitochondria
[94]
IP3K inhibition X-ray crystallography [138]
[139]
ERK modulation Aortic banding mouse
model. (Inhibition)
[119]
UV irradiated SKH
hairless mouse
(Inhibition)
[111]
SM43 rat mesangial
cell culture model
(Inhibition)
[100]
INS-1 cell culture
and rat Langerhans islet
preparation
(Activation)
[101]
Compound Effect Model(s) References
EGFR
downregulation
HT-29 colon cancer
culture model
[122]
ER stimulation T47D.Luc cell culture
luciferase reporter model
[8]
ANT inhibition Rat kidney cortex
mitochondria
[102]
MDR inhibition T5-HeLa membrane
vesicle preparations
[108]
Review [134]
Ca2+ channel
modulation
NG108-15 cell model [140]
PL-PK inhibition Mouse Brain Ca PL-PK [141]
Silychristin Pro-oxidant Ex vivo LDL oxidation
assay.
[95]
Antioxidant DPTT/DPTA ex vivo
model.
[99]
Rat mitochondria/
microsome models,
DPPH ex vivo assays.
[98]
DPTT/ORAC/HORAC/
TEAC/TAC ex vivo
model.
[142]
Huh7.5.1 cell model. [143]
Chemoprotection Rat cardiomyocyte
model.
[92]
Silydianin Pro-oxidant Ex vivo LDL oxidation
assay.
[95]
Antioxidant DPTT/ORAC/HORAC/
TEAC/TAC ex vivo
model.
[142]
Rat mitochondria/
microsome models,
DPPH ex vivo assays.
[98]
DPTT/DPTA ex vivo
model.
[99]
Huh7.5.1 cell model. [143]
Anti-inflammatory Isolated human PMNs.
Chemiluminescence
and O2•-formation.
[126]
Isolated human PMNs. [125]
Huh7.5.1 cell model. [143]
PPARγ
downregulation
3 T3-L1 cell model. [144]
Chemoprotection Rat cardiomyocyte
model.
[92]
Isosilybin PPARγ activation HEK-293 luciferase
reporter assays
[145]
Antioxidant ORAC/HORAC/TEAC/
TAC ex vivo model.
[142]
Huh7.5.1 cell model. [143]
Anti-inflammatory Human peripheral
blood mononuclear
cell model.
[143]
Antiviral (HCV) Huh7.5.1 cell model. [137]
Cell culture and ex
vivo models.
[129]
Increased Akt
Phosphorylation
Isosilybin B — prostate
cancer
cell culture models.
[118]
Decreased Akt
phosphorylation
Isosilybin A— prostate
cancer cell culture
models.
[117]
(continued) (continued)
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The hypothesis that silymarin protects tissue against ische-
mia, as highlighted in this text, is supported by a considerable
collection of evidence. However, neither the role that each
129A. Zholobenko, M. Modriansky / Fitoterapia 97 (2014) 122–132component of silymarin plays in the process, nor the timing is
entirely clear. To compound this, prevention of IR injury by
purified isosilybin, silychristin and silydianin has not yet been
tested.
The component responsible could be elucidated by large
scale cell culture based simulated ischemia studies, or better
small animal studies, designed to compare each of the com-
ponents side by side, along with the whole extract. At the
same time, themechanisms bywhich silymarin's components
cause cardioprotection should be cross-examined by observ-
ing the effects of inhibitors of the classic pathways of pre-
conditioning on silymarin induced cardioprotection. Whilst
cell culturemodels may be suitable for this type of study, they
possess several important disadvantages, including differ-
ences in metabolism and perfusion and the impossibility of
examining the effect of alterations in the immune system by
the formulation in question on IR injury. In addition, trans-
genic mouse models, such as those by Juhaszova et al. [27] or
Gomez et al. [28] would be very useful in elucidating whether
the effects of silymarin's components are due to true pre-
conditioning or antioxidant/radical scavenging effects. As
silymarin's components have been shown to affect markers
of inflammation, the use of a model that does not account for
the immune system when studying cardioprotection by
silymarin may leave the investigators with an incomplete
set of conclusions.
As there are numerous studies showing that silymarin is
generally safe when studying diseases of the liver [2,146],
clinical studies of silymarin or its components in cardiopro-
tection are not beyond the realms of possibility. It is ques-
tionable, however, whether a clinical trial that is capable of
advancing the field can be designed with the current under-
standing of the compounds in question.
5. Conclusion
Overall, the evidence seems to indicate that the constit-
uents of silymarin reduce the activity of both the Erk/MEK
and IP3K/Akt pro-survival pathways, whose activation is
central to ACh, bradykinin, and ouabain preconditioning. At
the same time, it makes sense that stimulation of oestrogen
receptors, inhibition of MMPs, PDEs, and mitochondrial ROS
generation by silymarin's components should facilitate pre-
conditioning. Furthermore the antiinflammatory properties of
certain components may also have a role to play in protecting
tissue from IR.
As we have highlighted in this review, deciphering the
mechanisms of action of silymarin in preconditioning is a
fairly involved affair. Summary of available literature shows
that silymarin and its components do influence signalling
pathways, which are involved in preconditioning. Whilst the
major component of silymarin, silybin, is the usual suspect
when it comes to these salutatory properties, other, minor
components of the extract have also been shown to possess
an important cardioprotective activity. With this in mind, it is
our belief that the individual components of silymarin con-
stitute a family of compounds worth investigating in relation
to ischemia reperfusion. Mechanisms of their action, if prop-
erly understood, promise a relatively inexpensive way of
broadening the spectrum of pharmacological agents available
for treatment of ischemia reperfusion injury.Conﬂicts of interest
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